Darifenacin Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413470

CAS#: 133099-04-4 (free base)

Description: Darifenacin Free Base is a Muscarinic M(3) receptor antagonist that is indicated for use in treatment of overactive bladder disorder.


Chemical Structure

img
Darifenacin Free Base
CAS# 133099-04-4 (free base)

Theoretical Analysis

MedKoo Cat#: 413470
Name: Darifenacin Free Base
CAS#: 133099-04-4 (free base)
Chemical Formula: C28H30N2O2
Exact Mass: 426.2307
Molecular Weight: 426.56
Elemental Analysis: C, 78.84; H, 7.09; N, 6.57; O, 7.50

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 133099-04-4 (free base)   133099-07-7 (HBr)    

Synonym: Darifenacin Free Base; Emselex; UK88525; UK 88525; UK-88525

IUPAC/Chemical Name: (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide

InChi Key: HXGBXQDTNZMWGS-RUZDIDTESA-N

InChi Code: InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1

SMILES Code: O=C(N)C(C1=CC=CC=C1)(C2=CC=CC=C2)[C@H]3CN(CCC4=CC=C(OCC5)C5=C4)CC3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: to be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 426.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Darifenacin. 2017 Jul 7. PMID: 31644105.

2: Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. doi: 10.2165/00003088-200645040-00001. PMID: 16584282.

3: Seo MS, An JR, Jung HS, Kang M, Heo R, Han ET, Yang SR, Park H, Jung WK, Choi IW, Bae YM, Na SH, Park WS. Suppression of voltage-gated K+ channels by darifenacin in coronary arterial smooth muscle cells. Eur J Pharmacol. 2021 Jan 15;891:173707. doi: 10.1016/j.ejphar.2020.173707. Epub 2020 Oct 31. PMID: 33137332.

4: Croom KF, Keating GM. Darifenacin: in the treatment of overactive bladder. Drugs Aging. 2004;21(13):885-92; discussion 893-4. doi: 10.2165/00002512-200421130-00005. PMID: 15493952.

5: Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004 Apr;45(4):420-9; discussion 429. doi: 10.1016/j.eururo.2004.01.008. PMID: 15041104.

6: Steers WD. Darifenacin: Pharmacology and clinical usage. Urol Clin North Am. 2006 Nov;33(4):475-82, viii. doi: 10.1016/j.ucl.2006.06.007. PMID: 17011383.

7: Haab F. Darifenacin in the treatment of overactive bladder. Drugs Today (Barc). 2005 Jul;41(7):441-52. doi: 10.1358/dot.2005.41.7.891719. PMID: 16193097.

8: Kissane LM, Martin KD, Meyer I, Richter HE. Effect of darifenacin on fecal incontinence in women with double incontinence. Int Urogynecol J. 2020 Jun 15:10.1007/s00192-020-04369-3. doi: 10.1007/s00192-020-04369-3. Epub ahead of print. PMID: 32542466; PMCID: PMC7736065.

9: Parsons M, Robinson D, Cardozo L. Darifenacin in the treatment of overactive bladder. Int J Clin Pract. 2005 Jul;59(7):831-8. doi: 10.1111/j.1368-5031.2005.00585.x. PMID: 15963212.

10: Dubinskaya A. Commentary: effect of darifenacin on fecal incontinence in women with double incontinence. Int Urogynecol J. 2020 Jun 17. doi: 10.1007/s00192-020-04387-1. Epub ahead of print. PMID: 32556847.